Cancer Cachexia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 113 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cancer Cachexia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cancer Cachexia - Pipeline Review, H2 2014', provides an overview of the Cancer Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cancer Cachexia Overview 9
Therapeutics Development 10
Pipeline Products for Cancer Cachexia - Overview 10
Pipeline Products for Cancer Cachexia - Comparative Analysis 11
Cancer Cachexia - Therapeutics under Development by Companies 12
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14
Cancer Cachexia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cancer Cachexia - Products under Development by Companies 18
Cancer Cachexia - Products under Investigation by Universities/Institutes 19
Cancer Cachexia - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Eli Lilly and Company 21
Novartis AG 22
Aphios Corporation 23
GTx, Inc. 24
Incyte Corporation 25
AEterna Zentaris Inc. 26
Helsinn Healthcare S.A. 27
Radius Health, Inc. 28
Vicus Therapeutics, LLC 29
Ohr Pharmaceutical Inc. 30
KAEL-GemVax Co., Ltd. 31
RaQualia Pharma Inc. 32
Acacia Pharma Ltd. 33
PsiOxus Therapeutics, Ltd. 34
Signablok, Inc 35
Myomics, Inc. 36
Cancer Cachexia - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
enobosarm - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
anamorelin hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
macimorelin acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ruxolitinib phosphate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(megestrol acetate + formoterol fumarate) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(etodolac + propranolol hydrochloride) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OHR/AVR-118 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MT-102 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LY-2495655 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
bimagrumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
VK-5211 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
dronabinol - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
tertomotide - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RAD-140 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DCB-CA2 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NBD Peptide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ATA-842 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
EXT-400 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RQ-00432933 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule for Cancer Cachexia - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Synthetic Peptides for Cancer Cachexia - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cancer Cachexia - Recent Pipeline Updates 85
Cancer Cachexia - Dormant Projects 104
Cancer Cachexia - Discontinued Products 105
Cancer Cachexia - Product Development Milestones 106
Featured News & Press Releases 106
Dec 11, 2013: Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan 106
Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer 107
Mar 21, 2013: Ohr Pharma Announces Results From OHR/AVR118 Phase II Trial In Cancer Cachexia 108
Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology 109
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 110
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 111
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Tables
Number of Products under Development for Cancer Cachexia, H2 2014 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Cancer Cachexia - Pipeline by Amgen Inc., H2 2014 20
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2014 21
Cancer Cachexia - Pipeline by Novartis AG, H2 2014 22
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2014 23
Cancer Cachexia - Pipeline by GTx, Inc., H2 2014 24
Cancer Cachexia - Pipeline by Incyte Corporation, H2 2014 25
Cancer Cachexia - Pipeline by AEterna Zentaris Inc., H2 2014 26
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2014 27
Cancer Cachexia - Pipeline by Radius Health, Inc., H2 2014 28
Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2014 29
Cancer Cachexia - Pipeline by Ohr Pharmaceutical Inc., H2 2014 30
Cancer Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 31
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2014 32
Cancer Cachexia - Pipeline by Acacia Pharma Ltd., H2 2014 33
Cancer Cachexia - Pipeline by PsiOxus Therapeutics, Ltd., H2 2014 34
Cancer Cachexia - Pipeline by Signablok, Inc, H2 2014 35
Cancer Cachexia - Pipeline by Myomics, Inc., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Cancer Cachexia Therapeutics - Recent Pipeline Updates, H2 2014 85
Cancer Cachexia - Dormant Projects, H2 2014 104
Cancer Cachexia - Discontinued Products, H2 2014 105